Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...
At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...
Hosted on MSN13d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
Allspring Global Investments Holdings LLC decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the ...
Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered ...
Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...
As the second day of AGBT came to a close, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, chatted with Kevin Davies, PhD, GEN ‘s Editorial Director, about some of the biggest announcements from ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results